問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Psychiatric Center,MOHW (在職)

Division of Psychiatry

Taoyuan Psychiatric Center,MOHW (在職)

Division of Psychiatry

更新時間：2023-09-19

廖定烈
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

1Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

廖定烈

List

12Cases

2021-10-01 - 2025-04-18

Phase III

Completed
An open label, single arm, extension trial to examine long-term safety of BI 425809 once daily in patients with schizophrenia who have completed previous BI 425809 Phase III trials (CONNEX-X)

  • Condition/Disease

    schizophrenia

  • Test Drug

    BI 425809

Participate Sites
10Sites

Not yet recruiting9Sites

Recruiting1Sites

2021-04-01 - 2024-12-18

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Not yet recruiting1Sites

Recruiting10Sites

2010-11-01 - 2012-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2010-09-01 - 2012-12-31

Phase III

A multicenter, randomized, double-blind, fixed-dose, 6-week trial of the efficacy and safety of asenapine compared with placebo in subjects with an acute exacerbation of schizophrenia (Phase 3 ; Protocol No. P06124)

  • Condition/Disease

    Schizophrenia

  • Test Drug

    Asenapine (SCH 900274)

Participate Sites
13Sites

Terminated13Sites

黃宗正
National Taiwan University Hospital

Division of Psychiatry

2010-10-01 - 2014-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

2012-01-05 - 2013-06-30

Phase III

A phase 3, multicenter, randomized, double-blind, placebo-controlled Trial of Fixed-dose OPC-34712 (4,2, and 1 mg/day) in the Treatment of Adults With Acute Schizophrenia

  • Condition/Disease

    Schizophrenia

  • Test Drug

    OPC-34712

Participate Sites
4Sites

Terminated4Sites

藍先元
China Medical University Hospital

Division of Psychiatry

2012-03-30 - 2014-06-30

Phase III

A phase 3, Multicenter, Open-label trial to evaluate the Safety and Tolerability of Oral OPC-34712 as Maintenance Treatment in Adults with Schizophrenia

  • Condition/Disease

    Schizophrenia

  • Test Drug

    OPC-34712

Participate Sites
4Sites

Terminated4Sites

藍先元
China Medical University Hospital

Division of Psychiatry

2012-05-01 - 2014-12-31

Phase II/III

  • Condition/Disease

  • Test Drug

Participate Sites
14Sites

Terminated14Sites

2012-05-01 - 2013-12-31

Phase II/III

  • Condition/Disease

  • Test Drug

Participate Sites
14Sites

Terminated14Sites

2008-12-01 - 2011-12-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB